Cart
sales@molnova.com
Bortezomib-pinanediol
CAS No. 205393-22-2
Bortezomib-pinanediol( —— )
Catalog No. M21104 CAS No. 205393-22-2
Bortezomib-pinanediol is a proteasome inhibitor. is a prodrug of Bortezomib.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 25MG | 34 | In Stock |
|
| 50MG | 47 | In Stock |
|
| 100MG | 68 | In Stock |
|
| 200MG | 100 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameBortezomib-pinanediol
-
NoteResearch use only, not for human use.
-
Brief DescriptionBortezomib-pinanediol is a proteasome inhibitor. is a prodrug of Bortezomib.
-
DescriptionBortezomib-pinanediol is a proteasome inhibitor. is a prodrug of Bortezomib.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayProteasome/Ubiquitin
-
TargetProteasome
-
RecptorProteasome
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number205393-22-2
-
Formula Weight518.462
-
Molecular FormulaC29H39BN4O4
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESCC(C)CC(NC(=O)C(Cc1ccccc1)NC(=O)c1cnccn1)B1OC2CC3CC(C3(C)C)C2(C)O1
-
Chemical NameN-((S)-1-(((R)-3-methyl-1-((3aS4S6S7aR)-3a55-trimethylhexahydro-46-methanobenzo[d][132]dioxaborol-2-yl)butyl)amino)-1-oxo-3-phenylpropan-2-yl)pyrazine-2-carboxamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Zhaoxin Gu Xiuxiu et al. Hyaluronic acid shell and disulfide-crosslinked core micelles for in vivo targeted delivery of bortezomib for the treatment of multiple myeloma.[J]. Acta Biomaterialia 2018.
molnova catalog
related products
-
Oprozomib
Oprozomib (ONX-0912;PR-047) is a potent, orally bioavailable proteasome inhibitor that inhibits chymotrypsin-like (CT-L) activity of 20S proteasome β5/LMP7 with IC50 of 36/82 nM.
-
Alloxan Monohydrate
Alloxan Monohydrate is a glucose analog used to induce diabetes by destroying beta-cells.
-
PR 39 (porcine)
Antibacterial peptide. Stimulates angiogenesis and inhibits inflammatory responses by selectively blocking proteasome degradation of IκBα.
